ISSN 1662-4009 (online)

ey0018.9-4 | Thyroid disorders in inflammatory bowel diseases | ESPEYB18

9.4. Infliximab therapy could decrease the risk of the development of thyroid disorders in pediatric patients with Crohn's Disease

A Furtak , AM Wedrychowicz , M Sladek , A Wedrychowicz , K Fyderek , J Starzyk

Front Endocrinol (Lausanne). 2020; 11: 558897. https://pubmed.ncbi.nlm.nih.gov/33042019/This patient cohort study evaluated the prevalence of autoimmune thyroid diseases (AITDs), defined as decreased thyroid echogenicity in 61 children with Crohn’s disease, 25 infliximab (IFX)-naïve (control group) and 36 IFX-treated patients (mean duration of IFX therapy 13.9±16.6 months). T...